Shorter hormone therapy as effective as longer course for prostate cancer

09/25/2013 | U.S. News & World Report

Short-term hormone therapy after radiation treatment had a comparable effect on overall survival and disease-specific survival as longer-course therapy in men with intermediate-risk prostate cancer, according to a study presented at a meeting of the American Society for Radiation Oncology. In the study of 133 patients, disease-specific survival was 96% for both short- and long-term hormone therapy groups while 10-year overall survival was 61% in the shorter-course group and 65% in the long-term group.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA